Metabolomic Alterations in Crimean Congo Hemorrhagic Fever Explored Through a Nationwide Study Using NMR Spectroscopy

1. Introduction

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe viral infection with substantial implications for public health in a wide range of countries in Asia, Africa, Southern Europe and the Middle East. CCHF is caused by CCHF virus (CCHFV) belonging to the genus of Orthonairovirus, and the family of Nairoviridae being one of deadliest viruses of its kind with reported mortality rate of 3-30% (1). CCHFV is transmitted to humans through tick bites of infected ticks, contact with blood or tissues of infected livestock, or contact with infected patients (2). The exact course of pathogenesis of CCHF is not clearly known however it is divided into four phases: incubation, pre-haemorrhagic, haemorrhagic and convalescence [2]. CCHF is classified as a severe hemorrhagic fever with a short incubation period of 1-3 days although longer incubation periods have been documented [3]. The onset of infection is often sudden and includes symptoms, fever, diarrhea, vomiting, nausea, myalgia, back and abdominal pain followed by an hemorrhagic phase where severe bruises, uncontrollable bleeding at the body orifices are observed and in severe cases, deterioration of kidneys, liver and lungs [4]. Deaths associated with the infection mostly occur between 5-14 days from the start of the viremic phase [5]. In terms of treatment, early hospitalizations and early administration of therapeutics are shown to reduce both severity and mortality of CCHF [6]. Hence, lack of early detection of CCHF is one of the leading factors causing the particular high mortality rate of CCHF.

There are several challenges of diagnosing CCHF infection particularly before the hemorrhagic phase of the infection and patients who are not suspected of being bitten by infected ticks or contacted with infected livestock. CCHF is comparatively uncommon in specific regions, which may lead healthcare providers to initially overlook it as a potential diagnosis. Likewise, there are documented cases of difficulties diagnosing CCHF, both because of the latter but also the absence of a universally applicable diagnostic kit for surveillance and diagnosis of all CCHFV strains [7]. Standard blood tests such as hemogram, biochemical analysis and physical examination at the beginning of hospitalization is applied on all patients who are suspected to be infected with CCHF although the results are often relevant for short term prognostic factors as biochemical values change often quickly. For more comprehensive and standard diagnostic methods, viral antigen and nucleic acid amplification tests are employed [8]. The initial symptoms of CCHF, such as fever, headache, and muscle aches, are rather non-specific hence diagnosing CCHF early by differential diagnosis can be difficult [5]. However biomarkers, essentially biomolecules, may provide a measure of specific diseases or their stages due to their varying concentrations. Bio markers are instrumental in diagnosing and monitoring the progression of viral infections. The associated changes in their levels, often indicative of the disease, are typically attributed to the host’s immune reaction and the disturbance of key biochemical routes in reaction to the infectious process. In this sense, omics studies and biomarkers could be used for both analysis and diagnosis of CCHF and for characterizing better treatment strategies of hospitalized patients swiftly is crucial to pinpoint optimal treatment strategies for treating CCHF [9].

So far there is only one omics study which investigates host-viral response and pathogenesis of CCHF utilizing transcriptomics and proteomics methods [10]. Led by this gap in the literature, we conducted a nationwide analysis of metabolomes of patients hospitalized due to CCHF. Turkey has over 10,000 cases of CCHF with an average fatality rate of 5%, making it a critical public health concern affecting people living in rural areas as ticks are widespread in these regions [11]. In our present investigation, we employed Nuclear Magnetic Resonance (NMR) spectroscopy exploratory metabolomics to investigate the overall temporal variations in plasma metabolites during a seasonal outbreak of CCHF infection. We employed PLS-DA statistical analysis of the blood serum metabolome of CCHF patients and categorized certain metabolomes linked to metabolic dysregulation caused by CCHF. Preliminary results from our study suggest that specific metabolic markers can be identified in the serum of CCHF patients pointing to metabolic dysregulation, which may allow for earlier diagnosis and more targeted treatment strategies. Additionally, being the first study to categorize alterations of patient metabolome during CCHF viremic phase may be valuable for efforts to develop therapeutics or targeted treatment strategies to reduce the severity and high mortality rate of CCHF.

2. Materials and methods

3. Results

In this study, 29 patients diagnosed with Crimean-Congo Hemorrhagic Fever (CCHF) and 10 healthy individuals serving as control subjects were included. The control group had a mean age of 50.1 years (range: 40–64 years), while the CCHF patient group had a slightly higher mean age of 50.5 years, with a wider age range of 22–77 years. A total of 126 blood samples were collected for analysis. Serum samples were prepared using methanol extraction, followed by Nuclear Magnetic Resonance (NMR) spectroscopy. The metabolite profiles obtained were subjected to comprehensive statistical analysis. This analysis incorporated data from all collected samples over four consecutive days and categorized them into moderate, severe, and control groups for comparative evaluation. Detailed procedures are described in the Materials and Methods section.

Partial Least Squares Discriminant Analysis (PLS-DA) was employed to develop a model incorporating the primary components (latent variables) of the dataset. The model focused on the first five components, which were pivotal for data classification and accounted for most of the dataset’s variance. The corresponding score plots, presented as two-dimensional graphs, illustrate the pairwise comparisons of these components (Figure 1a).

• Download figure
• Open in new tab

Figure 1

PLS-DA analysis of patient samples with severe and moderate infection level for four consecutive days with the control group (S: severe, M: moderate, C: Control) a. Matching score plots for the first five components of the PLS-DA analysis of all samples. b. partial Least Squares Discriminant Analysis score plot. c. Variable importance score plot in PLS-DA VIP Projection. d. corresponding compounds in detected increases on the spectra. Component 1: accuracy=0.817, (R2=0.246, Q2=0.142), component 2: accuracy=0.833, (R2=0.394, Q2=0.210), component 3: accuracy=0.809, (R2=0.545, Q2=0.225), component 4: accuracy=0.777, (R2=0.644, Q2=0.250), component 5: accuracy=0.769, (R2=0.782, Q2=0.205)

The PLS-DA score plot (Figure 1b) clearly differentiates between healthy and diseased individuals. PLS-DA, well-suited for handling high-dimensional data, effectively identifies the key variables responsible for distinguishing health states. This approach revealed a distinct separation based on variations and correlations within the biomarker data. To further explore the critical contributors to this separation, the Variable Importance in Projection (VIP) scores were analyzed. The PLS-DA VIP score plot (Figure 1c) highlights the variables with the most significant influence on the discrimination process, with the top 15 variables identified. VIP scores provide insights into the relevance of each variable, aiding in the identification of biomarkers that significantly differ between healthy and diseased states.

Figure 1c demonstrates that some data buckets exhibit lower concentration values (indicated in blue) in the control group, which progressively increase over time. Furthermore, the identified compounds displayed a marked increase in concentration, as corroborated by enhanced signals from their respective data buckets (Figure 1d).

Statistical analysis was performed across three distinct groups, incorporating samples collected over four days from both patient groups. While patient samples were successfully distinguished from the control group, no significant differences were observed between the moderate and severe disease groups. Key metabolites found to be elevated in the patient groups compared to controls included SAH, GTP, carnosine, maleate, 2-deoxyuridine, IMP, AMP, and NADP+.

As a secondary approach to data analysis, metabolite profiles were evaluated using samples collected on days 1 and 2 of hospitalization, representing the early stages of infection. Patients were categorized into severe and moderate groups based on clinical severity, while blood samples from healthy individuals were used as the control group for statistical comparisons (Figure 2). This focused analysis aimed to investigate metabolite changes during the initial phase of the disease. In addition to compounds identified in the initial analysis, novel metabolites with significant increases on days 1 and 2 were detected, suggesting their potential involvement in the pathogenesis of Crimean-Congo Hemorrhagic Fever (CCHF).

• Download figure
• Open in new tab

Figure 2

PLS-DA analysis of patient samples with severe and moderate infection level for first two days with the control group matching score plots for the first five components of the PLS-DA analysis of samples from day 1 and day 2 as labeled mild (M), severe (S) and compared with the control group (C). b, partial Least Squares Discriminant Analysis score plot. c, Variabl importance score plot in PLS-DA VIP Projection. d, corresponding compounds in detected increases on the spectra. Component 1: accuracy=0.0837, (R2=0.585, Q2=0.417), component 2: accuracy=0.821, (R2=0.627, Q2=0.433), component 3: accuracy=0.793, (R2=0.804, Q2=0.352)

A comprehensive metabolomic analysis of blood serum from CCHF patients revealed distinct metabolite patterns corresponding to infection severity. Partial Least Squares Discriminant Analysis (PLS-DA) score plots and Variable Importance in Projection (VIP) scores (Figure 3) highlighted notable differences in metabolite profiles between severe and moderate cases. In severe CCHF infections, metabolites such as AMP, IMP, and NAAD were significantly elevated in the serum, whereas these compounds were less prominent in samples from patients with moderate infection. Conversely, GTP was markedly increased in the moderate infection group but was not significantly detected in the severe group.

• Download figure
• Open in new tab

Figure 3

PLS-DA analysis of patient samples with moderate infection level for first two days with the control group and PLS-DA analysis of patient samples with severe infection level for first two days with the control group (S:severe, M: moderate, C:Control) a, partial Least Squares Discriminant Analysis score plot. Component 1: accuracy=0.983, (R2=0.821, Q2=0.739), component 2: accuracy=0.983, (R2=0.860, Q2=0.790), component 3: accuracy=0.983, (R2=0.954, Q2=0.829) b, Variable importance score plot in PLS-DA VIP Projection. c, partial Least Squares Discriminant Analysis score plot. Component 1: accuracy=0.950, (R2=0.857, Q2=0.702), component 2: accuracy=1, (R2=0,938, Q2=0.797), component 3: accuracy=1, (R2=0.982, Q2=0.824) d, Variable importance score plot in PLS-DA VIP Projection. e, corresponding compounds in detected increases on the spectra. f, corresponding compounds in detected increases on the spectra.

Overall, these findings highlight substantial metabolic differences between moderate and severe CCHF infections, pointing to critical pathways potentially involved in CCHF pathogenesis. These results underscore the importance of early-stage metabolite profiling to enhance our understanding of disease mechanisms and identify potential biomarkers for severity stratification.

4. Discussion

In this study, we present the first non-targeted metabolomics analysis of Crimean-Congo Hemorrhagic Fever (CCHF) to enhance the understanding of its pathogenesis, improve diagnostic capabilities, and aid in the development of potential therapeutic interventions. Using Nuclear Magnetic Resonance (NMR) spectroscopy, we identified significant increases in key metabolites, including S-adenosyl homocysteine (SAH), guanosine triphosphate (GTP), carnosine, maleate, 2’-deoxyuridine (2’-dU), inosine monophosphate (IMP), adenosine monophosphate (AMP), and nicotinamide adenine dinucleotide phosphate (NADP+), in the blood serum of CCHF patients. These findings suggest that these metabolites may play critical roles in the pathogenesis of CCHF and serve as important biomarkers for early detection and monitoring of disease progression.

Metabolomics has emerged as a powerful tool for studying host-pathogen interactions by revealing metabolic alterations induced by viral infections. To date, only one prior omics study utilizing mass spectrometry (MS) has investigated the interaction between the host and CCHF virus (CCHFV). Both NMR and MS are widely used in metabolomics, with each method offering distinct advantages depending on the research objectives. NMR spectroscopy is particularly suitable for non-targeted metabolomics due to its superior reproducibility, minimal sample preparation, and ability to analyze complex biofluids. It also provides consistent spectra across different instruments and laboratories, making it highly reliable for diagnostic and prognostic studies. On the other hand, MS offers higher sensitivity and is often preferred for targeted metabolomics studies.

The utility of NMR metabolomics has been demonstrated in the analysis of host metabolic changes induced by various viral infections, including HIV, dengue virus (DENV), and chikungunya virus. Moreover, metabolomics approaches have been successfully applied to study other viral hemorrhagic fevers, such as Ebola, Marburg, and dengue, yielding promising results for early diagnosis and prognosis prediction. Similarly, our findings underscore the potential of NMR metabolomics in elucidating the complex metabolic interactions between CCHFV and its host. The observed metabolic changes in CCHF patients offer new insights into the mechanisms of disease pathogenesis and highlight potential pathways for targeted therapeutic interventions.

By focusing on metabolite profiles in CCHF, this study demonstrates the value of NMR-based metabolomics in addressing the gaps in knowledge surrounding this severe disease. Our findings not only advance the understanding of CCHF pathogenesis but also provide a foundation for further research aimed at identifying effective biomarkers and therapeutic targets. These results emphasize the critical role of metabolomics in uncovering host-pathogen dynamics and improving clinical outcomes in viral infections.

Among the notable metabolites detected, S-adenosyl homocysteine (SAH) emerged as a significant intermediate in the metabolic pathways of CCHF patients. SAH, a precursor to homocysteine and adenosine, serves as the substrate for the enzyme SAH hydrolase, a critical component of the S-adenosylmethionine (SAM/AdoMet) regeneration cycle (Figure 4a). Elevated SAH levels were observed in CCHF patients early during hospitalization, underscoring its potential relevance in the disease’s pathogenesis. This observation aligns with findings from a genomic study linking Methylenetetrahydrofolate reductase (MTHFR) polymorphisms to a predisposition for milder forms of CCHF [18]. Since MTHFR plays a central role in folate metabolism and methylation processes, these results suggest that disruptions in methylation pathways during the viremic phase could serve as prognostic indicators for CCHF severity.

• Download figure
• Open in new tab

Figure 4

Main metabolic pathways of metabolites detected by metabolomics approach a. S-Adenosyl-L-homocysteine and nearest neighbor in Cysteine and methionine metabolism b. GTP and nearest neighbor in Purine metabolism c. Carnosine and nearest neighbor in Histidine metabolism d. Deoxyuridine and nearest neighbor in Pyrimidine metabolism

SAM is a key methyl donor in various cellular methylation reactions, including those involved in 5’ RNA capping, a process critical for viral replication and transcription [19]. Evidence from other viral families, such as flaviviruses [20], and Ebola, whose L protein exhibits methyltransferase activity, indicates that methylation mechanisms can influence RNA cap structure and internal adenosine-2’-O-methylation [21]. These parallels highlight the potential importance of methylation pathways in CCHF pathogenesis. The additional complexity of RNA methylation in some viral families suggests that SAM-related domains within viral replication complexes could represent promising therapeutic targets.

Our findings emphasize the need for further research into SAM-related pathways to unravel their implications for viral replication and host-pathogen interactions in CCHF. These pathways not only provide insight into disease mechanisms but also present opportunities for the development of targeted therapeutic interventions, particularly those aimed at disrupting key methylation processes critical for viral survival.

GTP, AMP, and inosine monophosphate (IMP) are key nucleotides involved in purine metabolism, essential for energy production and nucleic acid synthesis (Figure 4b). Elevated levels of GTP and IMP are well-documented indicators of viral infections, particularly among viruses in the Orthornavirae kingdom. In the context of CCHF, the increase in these purine metabolites aligns with the known mechanism of action of broad-spectrum antivirals like Ribavirin. As a nucleotide analog, Ribavirin targets the substrate-binding site of the IMPDH enzyme, thereby reducing RNA synthesis in infected cells by downregulating GTP synthesis [22]. Monitoring these metabolites could provide valuable insights into the efficacy of antiviral treatments. Additionally, quantifying shifts in GTP and IMP concentrations offers a potential strategy to optimize therapeutic interventions in clinical trials, enhancing the effectiveness of antiviral agents targeting purine metabolism [23].

Carnosine (β-alanyl-L-histidine) (Figure 4c), a dipeptide with antioxidant, anti-glycation, and anti-inflammatory properties, was also significantly elevated in CCHF patients. Predominantly found in skeletal muscle and the brain, increased carnosine levels may reflect a compensatory response to oxidative stress, infection-induced cell death, or muscle mass reduction due to hospitalization. Carnosine has demonstrated antiviral potential against Zika, dengue, and SARS-CoV-2, reducing viral replication and alleviating symptoms. While its therapeutic utility against CCHF remains to be established, these findings highlight the need for further investigation into its potential as a treatment option.

2’-Deoxyuridine (2’-dU), an intermediate in thymidylate synthesis (Figure 4d), also showed significant elevation in CCHF patients. This metabolite, a precursor for DNA synthesis, plays a role in antiviral therapies, such as Edoxudine, which target DNA viruses [24–26]. Variants of 2’-dU, such as BVDU, have shown efficacy against Herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) [27]. While 2’-dU is typically associated with DNA virus activity, its elevated levels in CCHF patients may suggest broader disruptions in pyrimidine metabolism, potentially linked to the metabolic dysregulation observed in this study.

Nicotinamide adenine dinucleotide phosphate (NADP+) serves as a critical cofactor in enzymatic reactions, primarily within the pentose phosphate pathway, where it supports fatty acid synthesis and the regeneration of reduced glutathione. Its role in redox reactions also underscores its importance in the antioxidant defense system. Elevated NADP+ levels in CCHF patients could reflect increased metabolic activity related to energy production and nucleotide synthesis. This hypothesis is further supported by the observed overlap in the elevations of NADP+, GTP, IMP, and AMP, indicating a coordinated upregulation of energy metabolism pathways. The significant increase in these metabolites in severe cases (Figure 3) underscores their potential relevance in disease progression and severity.

Maleate (cis-butenedioic acid), a dicarboxylic acid and trans-isomer of fumaric acid, plays a role in nicotinate and nicotinamide metabolism [29]. Elevated maleate levels in CCHF patients suggest underlying metabolic disruptions. Previous studies have demonstrated that maleate can inhibit the tricarboxylic acid (TCA) cycle, lower ATP levels, and impair enzymatic activity, leading to systemic metabolic imbalances. These findings warrant further investigation into the potential implications of maleate in the pathophysiology of CCHF [30].

In summary, these metabolomic findings reveal significant disruptions in purine, pyrimidine, and energy metabolism pathways in CCHF patients. Metabolites such as GTP, IMP, AMP, carnosine, 2’-dU, NADP+, and maleate provide valuable insights into the pathogenesis of the disease and highlight potential biomarkers for disease progression and therapeutic targets.

Conclusion

In this study, we conducted a nationwide analysis of blood serum metabolites from patients hospitalized due to Crimean-Congo Hemorrhagic Fever (CCHF), employing Nuclear Magnetic Resonance (NMR) spectroscopy as a novel approach to investigate host-pathogen interactions and the pathogenesis of CCHFV. Our findings revealed significant alterations in several key metabolites, including S-adenosyl homocysteine (SAH), guanosine triphosphate (GTP), inosine monophosphate (IMP), adenosine monophosphate (AMP), 2’-deoxyuridine (2’-dU), nicotinamide adenine dinucleotide phosphate (NADP+), carnosine, and maleate. Notable changes were observed in pathways related to the TCA cycle, nucleic acid synthesis, and redox-associated coenzymes, highlighting the systemic metabolic impact of CCHFV infection.

The elevation of metabolites such as SAH underscores the potential impact of methylation processes on CCHF pathogenesis and prognosis, linking viral replication to host epigenetic regulation. Similarly, the observed disruptions in purine metabolism, particularly the increased levels of GTP and IMP, suggest potential therapeutic implications, as these pathways are targeted by antiviral agents like Ribavirin. The role of other metabolites, such as carnosine and maleate, indicates a systemic response to oxidative stress and cellular damage, providing further insight into the host’s metabolic adaptation during infection.

Our findings align with prior metabolomics studies on other viral hemorrhagic fevers and highlight the utility of NMR-based metabolomics for uncovering biomarkers that may facilitate early diagnosis, prognosis prediction, and therapeutic development. The distinct metabolic profiles observed between moderate and severe CCHF cases further emphasize the relevance of these biomarkers in stratifying disease severity and monitoring treatment efficacy.

This study paves the way for future investigations to validate these biomarkers in larger cohorts and explore the therapeutic potential of targeting the identified pathways. By advancing the understanding of CCHF pathogenesis, our results contribute to the development of more effective diagnostic and therapeutic strategies, ultimately improving patient outcomes in this severe viral infection.

Author Contributions

Çağdaş Dağ: Conceptualization, Methodology, Supervision, Funding acquisition, Writing-Reviewing and Editing, Writing-Original draft preparation Kerem Kahraman: Investigation, Formal analysis, Visualization, Writing-Reviewing and Editing Oktay Göcenler: Investigation, Formal analysis, Writing-Original Draft, Visualization Derya Yapar: Investigation Yaren Kahraman: Investigation, Formal analysis Cengizhan Büyükdağ: Formal analysis, Writing-Original Draft Gülen Esken: Methodology, Investigation Serena Ozabrahamyan: Methodology, Investigation Tayfun Barlas: Investigation Yüksel Karadağ: Investigation Aysel Kocagül Çelikbaş: Investigation Füsun Can: Supervision, Investigation Nurcan Baykam: Supervision, Investigation Mert Kuşkucu: Supervision, Writing-Reviewing and Editing Önder Ergönül: Supervision, Funding acquisition, Conceptualization, Methodology